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Background: Grade IV chemotherapy toxicity is deﬁned as absolute neutrophil count <500/lL. The na-
dir is considered as the lowest neutrophil number following chemotherapy, and generally is not expected
before the 7th day from the start of chemotherapy. The usual prophylactic dose of rHu-G-CSF (Filgrastim)
is 300 lg/day, starting 24–48 h after chemotherapy until hematological recovery. However, individual
patient response is largely variable, so that rHu-G-CSF doses can be different. The aim of this study was
to verify if peripheral blood automated ﬂow cytochemistry and ﬂow cytometry analysis may be helpful in
predicting the individual response and saving rHu-G-CSF.
Methods: During Grade IV neutropenia, blood counts from 30 cancer patients were analyzed daily by
ADVIA 120 automated ﬂow cytochemistry analyzer and by Facscalibur ﬂow cytometer till the nadir.
‘‘Large unstained cells’’ (LUCs), myeloperoxidase index (MPXI), blasts, and various cell subpopulations
in the peripheral blood were studied. At nadir rHu-G-CSF was started and 81 chemotherapy cycles were
analyzed. Cycles were stratiﬁed according to their number and to two dose-levels of rHuG-CSF needed to
recovery (300–600 vs. 900–1200 lg) and analyzed in relation to mean values of MPXI and mean abso-
lute number of LUCs in the nadir phase. The linear regressions of LUCs % over time in relation to two
dose-levels of rHu-G-CSF and uni-multivariate analysis of lymphocyte subpopulations, CD341 cells,
MPXI, and blasts were also performed.
Results: In the nadir phase, the increase of MPXI above the upper limit of normality (>10; median
27.7), characterized a slow hematological recovery. MPXI levels were directly related to the cycle num-
ber and inversely related to the absolute number of LUCs and CD341/CD451 cells. A faster hematologi-
cal recovery was associated with a higher LUC increase per day (0.56% vs. 0.25%), higher blast
(median 36.7/lL vs. 19.5/lL) and CD341/CD451 cell (median 2.2/lL vs. 0.82/lL) counts.
Conclusions: Our study showed that some biological indicators such as MPXI, LUCs, blasts, and
CD341/CD451 cells may be of clinical relevance in predicting individual hematological response to rHu-
G-CSF. Special attention should be paid when nadir MPXI exceeds the upper limit of normality because
the hematological recovery may be delayed. VC 2009 Clinical Cytometry Society
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Automated ﬂow cytochemistry analysis, using ADVIA
120 hematology analyzer or Technicon H2 (1), classiﬁes
and measures leukocytes using white light and laser
technology by means of two separate channels: the per-
oxidase channel, which identiﬁes, through tungsten-
based optics and cytochemistry, the different types of
leukocytes [neutrophils, monocytes, eosinophils, lym-
phocytes, and large unstained cells (LUCs)] on the basis
of their size and staining properties. Basophil/lobularity
channel, which uses the laser light scattering system,
provides valuable information about the maturity degree
of each white blood cell nucleus measuring nuclear
lobularity and density, thus allowing the identiﬁcation of
the so called ‘‘blasts.’’ LUCs are reported on hemogram
when large peroxidase-negative cells in peripheral blood
cannot be characterized further as large lymphocytes,
‘‘virocytes,’’ or stem cells. LUCs have been studied in the
diagnosis (1) and monitoring (2,3) of acute leukemias
and myelodysplastic syndromes (4). They have been
considered as prognostic factors in B-CLL (5) and in the
diagnosis and monitoring of viral infectious diseases (6).
During Grade IV chemotherapy-induced neutropenia,
LUCs increase in peripheral blood and are correlated to
CD34þ cells and large lymphocytes of helper phenotype
in prenadir phase (7). Bayer hematology analyzer can
also measure the myeloperoxidase intracellular index
(MPXI). MPXI may raise in patients with unstable angina
and acute myocardial infarction, following treatment
with granulocyte-colony stimulating factor (G-CSF), and
in lymphoma transplant patients who develop bactere-
mia (8).
By deﬁnition, the nadir is considered as the lowest
leukocyte count following chemotherapy, and is
strictly dependent on the type of chemotherapy sched-
ule. In general, a postchemotherapy neutrophil nadir is
not expected before 7th day from the start of chemo-
therapy (9).
Recombinant human G-CSF has been shown to reduce
the severity and duration of neutropenia (10). The pri-
mary prophylaxis with rHu-GCF has demonstrated a
reduction of febrile neutropenia (FN) risk, mortality
related to infections and early deaths. These ﬁndings are
not connected with malignancies and chemotherapy reg-
imens (11). When chemotherapy regimens with a FN
incidence exceeding 20% are used, G-CSF has shown to
be of proven efﬁcacy and thus recommended (12). The
recommended dose of rHu-G-CSF is 5 lg/kg/day subcuta-
neously starting 24–48 h after the end of chemotherapy
until an absolute neutrophil count (ANC) of 10,000/lL
is achieved.
Recent data suggest that less frequent dosing sched-
ules, i.e. administration of G-CSF at the 8th and 12th day
after chemotherapy, may equally prevent neutropenia
and chemotherapy delay (13).
The current opinion is that additional studies are
needed to guide clinicians in the most effective and
cost-effective use of G-CSF prophylaxis in patients at
low risk of FN without serious comorbidities or life-
threatening complications (11).
The main objective of this study was to evaluate if pe-
ripheral blood automated ﬂow cytochemistry and ﬂow
cytometry analysis data may help in predicting the
response to rHu-G-CSF when administered at the nadir.
MATERIALS AND METHODS
Patient Characteristics
Thirty patients without major comorbidities were
included in the study; 22 women and 8 men. Median age
was 55 years (range 35–75). The data derived from
patients with FN or requiring transfusions or affected by
primary and secondary myeloperoxidase deﬁciency were
excluded. None of the lymphoma patients had bone mar-
row involvement at the time of the study. The chemother-
apy regimens selected were: doxorubicin þ paclitaxel
(ADM-PCX) or epidoxorubicin þ cychlophosphamide þ
ﬂuorouracile (FEC) standard dose for breast cancer in 22
cases; cis-diaminedichloroplatinum þ etoposide for non–
small cell lung cancer in two cases; methotrexate þ vin-
blastine þ doxorubicin þ cis-diaminedichloroplatinum
(M-VAC) for bladder cancer in one case; mitoxantrone þ
cychlophosphamide þ vincristine þ prednisone (CNOP)
for B-cell lymphoma in two cases; vinblastine þ ifosfamide
þ cis-diaminedichloroplatinum (DICE) for testicular can-
cer in two cases; epidoxorubicin þ cis-diaminedichloro-
platinum þ ﬂuorouracile (ECF) for gastric cancer in one
case. All chemotherapy regimens had an expected nadir
after 7 days from chemotherapy (8).
After verbal informed consent, we planned one com-
plete blood count before chemotherapy, one at day 7
and then every 3 days. When the neutrophils were
<500/lL, the blood counts were repeated daily till nadir.
The study was restricted only to cycles in which ANC
remained below 500/lL for at least 2 days. Contempora-
neously, blood samples were collected into ethylene-
diaminotetracetic acid tubes and sent to the University
of Ferrara, Section of Hematology within 12 h from phle-
botomy for leukocyte subpopulations assessment.
Subcutaneous injections of 300 lg/day of rHu-G-CSF (Fil-
grastim, Neupogen-Hoffmann La Roche Ltd-Switzerland-
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Amgen, Thousand Oaks, CA) were started at nadir and
continued daily, monitoring neutrophil count, until ANC
reached at least 2,000/lL. A total of 81 chemotherapy
cycles were studied, with a median of two cycles per
patient (range 1–4).
ADVIA Leukocyte Hematology Analyzer
The blood counts for the determination of LUCs,
MPXI, and blasts were performed by ADVIA 120 (Bayer
Corporation, Tarrytown, NY) or Technicon H2 auto-
mated ﬂow cytochemistry analyzer (1). MPXI is a param-
eter derived from the mean position on the x-axis of an
archetypal population of neutrophils and is a direct and
routine reading parameter in the machine result with
the normal range of 10 to þ10. It has been used to
study in vitro neutrophils activation (14) and to detect
the presence of myeloperoxidase deﬁciency (15).
Lymphoma Patients Undergoing a Mobilization Regimen
At the same time, at the University of Ferrara, Section
of Hematology, a group of patients with Hodgkin’s and
non-Hodgkin’s lymphoma (NHL) undergoing a mobiliza-
tion regimen was used as control. In brief, 93 patients,
72 NHL and 21 Hodgkin’s disease, treated with a cyclo-
phosphamide-based mobilization regimen (3 g/m2) were
studied during neutropenia before collection of hemo-
poietic peripheral blood cells. The aim was to correlate
the number of peripheral blood CD34þ cells with the
absolute number of LUCs, 10–12 days after high dose
chemotherapy. NHL patients were subdivided according
to the histological grading (WHO classiﬁcation).
Flow Cytometry Analysis
For ﬂow cytometry analysis, all blood samples were
analyzed with a Facscalibur ﬂow cytometer (Becton
Dickinson, San Jose`, CA) equipped with a 15 mW argon-
ion laser. For each sample, 20,000 cells were analyzed at
a ﬂow rate of 300 particles per second. Peripheral
blood lymphocyte populations were studied using a
panel of monoclonal antibodies (MoAbs) including CD2,
CD3, CD56, CD4, CD8, and CD19 (Becton-Dickinson,
Milan, Italy). Cells were incubated for 30 min with
10 lL ﬂuorescein isothiocyanate (FITC), phycoerythrin
(PE), or per-CP conjugated MoAbs, washed twice with
PBS solution, then lysed with FACS lysing solution (BD)
for 10 min. A three- to four-color cytoﬂuorimetric analy-
sis was performed. Enumeration of CD34þ cells was per-
formed using a PE conjugated anti-CD34 (HPCA-2) and a
FITC conjugated anti-CD45 (BD) and according to ISH-
AGE guidelines (16).
Statistical Analysis
Blood counts of each chemotherapy cycle requiring
the same dose of rHu-G-CSF to reach 2,000 neutrophils
were assembled.
Cycles were stratiﬁed according to their number and
to the four dose-levels of rHu-G-CSF and analyzed in rela-
tion to mean nadir values of MPXI and mean absolute
number of LUCs (Table 1).
A t-test of difference in two means was used. Accord-
ing to the previous reports (13), two dose groups of
rHu-G-CSF were analyzed: Group 1, 300–600 lg (corre-
sponding to 1–2 days of G-CSF therapy); Group 2, 900–
1200 lg (corresponding to 3–4 days of G-CSF treat-
ment). Mono- and multivariate analyses of MPXI, blasts,
CD34þ cells, and lymphocyte subpopulations were
carried out.
Simple linear regressions were performed between
time and LUCs, before rHu-G-CSF administration; t-tests
were used to compare the deriving slopes. Kruskal–
Wallis analyses were used to verify possible differences
between the two dose-level groups of rHu-G-CSF (Table
3) working with a test power of 90%. Binary logistic
regressions were also devoted to reveal possible factors
that should differently characterize the membership to
the two different dose groups (ODD ratio). ‘‘STAT-
GRAPHICS’’ v.4.0 (STSG, Inc., Rockville, MD) and NCSS-
PASS v.6 (J.L. Hintze Kaysville, UT) were used to perform
statistical analysis. The Pearson correlation model was
used to compare the data of lymphoma patients.
RESULTS
When administered at nadir, a total dose of rHu-G-CSF
ranging from 300 (only one administration) to 1,200 lg
(four administrations in 4 consecutive days) was sufﬁ-
cient to reach at least a count of 2,000 neutrophils/lL
in all patients. LUC and MPXI values in the different
cycles of chemotherapy are reported in Table 1: the
number of cycles with Grade IV neutropenia was similar
from Cycle 1 to 4 or more. The number of the cycles
and of the rHu-G-CSF doses were directly related to the
Table 1
Relationship Between MPXI, LUCS, rhu-G-CSF Doses, and Cycle Number
rHu-G-CSF
Doses


















300 lg 14 2.5 125 9 5 90 6 25 310 7 8.5 85
600 lg 6 1.5 40 8 15 20 5 10 30 9 18 40
900 lg 3 15 45 5 16 30 0 – – 2 32 40
1200 lg 0 – – 1 25 30 1 26 40 5 31 30
Total 23 23 12 23
With the increase of cycle number and the rhu-G-CSF dose, the mean value of MPXI and LUCs become highly statistically differ-
ent (P < 0.001).
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mean MPXI values and inversely related to the absolute
number of LUCs. In particular, the mean absolute num-
ber of LUCs in Group 1, at ﬁrst cycle, was statistically
higher than in Group 2 at fourth cycle (P < 0.05); on
the contrary, the mean value of MPXI was higher in
Group 2 at Cycle 4 or more, than that in Group 1 at the
ﬁrst cycle (P < 0.05). The ﬁrst cycles of chemotherapy
needed a signiﬁcantly rHu-G-CSF lower dose to reach
hematological recovery than the following cycles (v2
test, P < 0.01). The linear regression analysis between
LUCs % and time in the two groups of doses (Fig. 1)
showed a direct statistical correlation between the inter-
cept of Group 1 (4.3 with a slope of 0.49) and the inter-
cept of Group 2 (4.13 with a slope of 0.25). The
comparison between the regression coefﬁcients of the
two curves documented a highly statistically signiﬁcant
difference. LUC increase per day in Group 1 was 0.56%,
whereas it was 0.25% in Group 2. The immunopheno-
typic proﬁle of peripheral blood cells was carried out to
characterize the two groups of doses of rHu-G-CSF in a
better way. We compared MPXI values, blasts, CD34þ
cells, and lymphocyte subpopulations. All data refer to
the nadir phase and were analyzed without distinction
among cycle numbers (Table 2). The mean MPXI value
of Group 1 (11.6) was statistically lower than that of
Group 2 (22.2), the mean absolute number of blasts of
Group 1 (40.9/lL) was signiﬁcantly higher than that in
Group 2 (22.1/lL); the mean absolute number of
CD34þ/CD45þcells of Group 1 (4.2/lL) was signiﬁcantly
higher than that of Group 2 (0.74/lL) (Table 2). On the
contrary, the mean absolute number of CD3þ/CD4þ
cells, CD3þ/CD8þ cells, CD3/CD56þ/CD2þ cells, and
CD3þ/HLA-DRþcells did not differ signiﬁcantly between
the two groups. ODD ratios indicated that the increase
of MPXI better characterized the Group 2 membership
(Table 3). On the contrary, the increase of blasts,
CD34þ/CD45þ individualized mainly Group 1. The mobi-
lization of CD34þ/CD45þ cells in peripheral blood
occurred during neutropenia, after standard dose chem-
otherapy. Cycles with a higher number of hematopoietic
progenitor cells in peripheral blood needed lower doses
of growth factor to recover from neutropenia. Correla-
tions between LUCs and CD34þ cells in peripheral
blood during Grade 4 neutropenia was in accordance
with data from lymphoma patients undergoing a mobili-
zation regimen.
Lymphoma Patient Group Treated with a
Mobilization Regimen
The analysis of lymphoma patients treated with a cy-
clophosphamide-based mobilization regimen (3–4 g/m2)
showed a direct correlation between the number of
circulating LUCs with the number of peripheral blood
CD34þ/CD45þ cells (whole group: r ¼ 0.80; P < 0.01;
HL: r ¼ 0.86; NHL: r ¼ 0.63; low-grade NHL: r ¼ 0.95;
high-grade NHL r ¼ 0.71) at 10–12 days after chemo-
therapy (nadir phase).
DISCUSSION
Since the ideal schedule for rHu-G-CSF prophylaxis
remains to be established, it is important to deﬁne fac-
tors which inﬂuence duration and depth of neutropenia.
The risk factors so far studied are the following: chemo-
therapy regimens, patients’ age, poor performance sta-
tus, and renal and liver impairment (17). In our study,
we have analyzed some biological indicators that may
inﬂuence the response to rHu-G-CSF, after standard dose
FIG. 1. Comparison between the regression lines with 95% conﬁ-
dence limits relative to the two dose Groups (300–600 lg and 900–
1200 lg). LUCs increase per day in Group 1 was 0.56%, whereas it
was 0.25% in Group 2.
Table 2
Measurement of Hematological and Phenotypical Parameters Using Automated Flow Cytochemistry and
Flow Cytometry Technologies
Variable
Group 1: dose 300–600 lg Group 2: dose 900–1200 lg
Signif.Mean SD Median Mean SD Median
MPXI 11.6 7.2 11.3 22.2 8.3 27.7 P < 0.05
Blasts/lL 40.9 27.9 36.7 22.15 10.4 19.5 P < 0.05
CD34þ/CD45þ/lL 4.2 4.3 2.2 0.74 0.71 0.82 P < 0.01
CD3þ/HLA-DRþ/lL 70.40 59.3 49.6 80.5 37.1 67.3 NS
CD3þ/CD4þ/lL 408.9 280.7 356.1 251.1 193.9 199.8 NS
CD3þ/CD8þ/lL 222.4 157.9 179.5 161.3 36.3 162.2 NS
CD3/CD56þ/CD2þ/lL 158.7 110.9 129.6 98.9 52.5 82.9 NS
Comparison of absolute number of different variables for dose levels 1 and 2 of G-CSF.
SD, standard deviation.
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chemotherapy. Higher MPXI value (median 22  8) in
the nadir phase, when neutrophils are <500/lL, charac-
terized poor responders (Tables 1, 2, and 3). Myeloper-
oxidase is contained in neutrophil azurophil granules.
We examined blood smears during Grade IV neutropenia
by microscopy to assess the size and morphology of
neutrophils and found few hyper segmented neutrophils
without visible alteration of granule content. Neutrophil
maturation needs the sequential activation of several
genes such as GATA-1, GATA-2, PU.1, c-myb, besides sev-
eral genes of the C/EBP family (18). It may be stressed
that chemotherapy, in selected cases, interferes with this
complex gene cooperation. The very high level of MPXI
in the nadir phase may be due to a delay of neutrophil
maturation with delayed appearance in peripheral blood
of CD34þ/CD45þ cells, LUCs, and blasts. The American
Society of Clinical Oncology has developed practice
guidelines for the use of CSFs (12). Despite these recom-
mendations, the literature data conﬁrm that the schedul-
ing of rHu-G-CSF is extremely variable among different
authors ranging from 2 days (19) to 14 days (20) or until
recovery of 10,000 neutrophils/lL (21,22). In the
Papaldo et al. (13) study, one group of patients was
treated prophylactically with 300 lg on the 8th and
12th day after chemotherapy. No differences were
observed in the rate of FN in this group, compared with
the more intensive treatments. In our study, we have
observed that when administered at nadir, the dose of
rHu-G-CSF necessary to restore neutropenia induced by
standard dose chemotherapy, ranged from 300 to 1200
lg. We have also shown some biological parameters that
can help to identify good responder patients who may
be treated with only 300–600 lg of rHu-G-CSF. Indeed
the increase of LUC percentage, related to CD34þ cells,
blasts, and normal or low MPXI observed in the nadir
phase, is statistically correlated to the prompt response
to the treatment. Our data suggest to pay major atten-
tion when treating patients prophylactically with rHu-G-
CSF, in particular, if elderly or affected by some comor-
bidities and that show high level of MPXI (>10) and
low increase LUCs % (<0.25% per day) in the nadir
phase. As a matter of fact, the response to rHu-G-CSF in
these cases may be delayed. We found an inverse corre-
lation between the number of CD34þ/CD45þ cells,
blasts in peripheral blood, and MPXI in the nadir phase.
Our results also prove that chemotherapy cycles charac-
terized by a higher MPXI (>10), mobilize a lower num-
ber of CD34þ/CD45þ cells in peripheral blood. To our
knowledge these observations were not previously
reported. The results obtained from lymphoma patients
treated with high-dose chemotherapy conﬁrmed a direct
positive correlation between the absolute number of cir-
culating LUCs counted by ADVIA system and peripheral
blood CD34þ/CD45þ cells detected by ﬂow cytometry,
and highlight the role played by LUCs in the hematopoi-
esis recovery after chemotherapy as suggested by Green-
ﬁeld et al. (23). The problem of unexplained poor
mobilizers still remains to be clariﬁed.
In conclusion, some biological indicators such as MPXI
and LUCs may be predictive of individual hematological
response to rHu-G-CSF. During the nadir phase, MPXI
above the upper normal limit was associated to slow
CD34þ/CD45þ cell mobilization, reduced increase of
LUCs per day and low circulating blasts. All those varia-
bles were able to characterize a delayed hematological re-
covery in cancer patients treated with chemotherapy. Our
study further shows that the monitoring of the earlier-
described parameters may be helpful for improving rHu-
G-CSF utilization and for optimizing cost effectiveness, in
particular in patients without serious comorbidities, at
low risk of FN and life-threatening complications.
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